Quote:

---

"Amarantus is poised to become a leading company on the cutting edge of neurodegenerative disease diagnostic and drug development," said Iain Ross, a newly-appointed member of the Amarantus Board of Directors. "The Company has made several key strategic decisions in the last two years that have led to significant appreciation in shareholder value and scientific creditability. As the Company continues on this trajectory, I believe I will be able to bring significant experience and expertise in strategic planning and execution that will pave the way for continued shareholder value creation. I am extremely pleased to be joining Amarantus as it works toward listing its common shares on a national stock exchange in the United States."

---